Authors: Arikan, S.; Rex, J.H.

Source: Current Pharmaceutical Design, Volume 7, Number 5, 1 March 2001 , pp. 393-415(23)

Publisher: Bentham Science Publishers

Abstract:

Immunocompromised patients are well known to be predisposed to developing invasive fungal infections. These infections are usually difficult to diagnose and more importantly, the resulting mortality rate is high. The limited number of antifungal agents available and their high rate of toxicity are the major factors complicating the issue. However, the development of lipid-based formulations of existing antifungal agents has opened a new era in antifungal therapy. The best examples are the lipid-based amphotericin B preparations, amphotericin B lipid complex (ABLC Abelcet), amphotericin B colloidal dispersion (ABCD Amphotee or Amphocil), and liposomal amphotericin B (AmBisome). These formulations have shown that antifungal activity is maintained while toxicity is reduced. This progress is followed by the incorporation of nystatin into liposomes. Liposomal nystatin formulation is under development and studies of it have provided encouraging data. Finally, lipid-based formulations of hamycin, miconazole, and ketoconazole have been developed but remain experimental. Advances in technology of liposomes and other lipid formulations have provided promising new tools for management of fungal infections.

Keywords: Lipid-based Antifungal Agents; Candida spp; Aspergilus; Fusarium spp; Liposomes; Crytococcus neoforman; Amphotericin; Amphoteicin B Lipid Complex; Amphoteicin B Lipid Complex; Liposomal Amphotericin B; Liposomal Nystatin

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612013398031

Publication date: 2001-03-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Arikan, S. ;  Rex, J.H.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers